Treatment of HIV infection with once-daily regimens

Bibliography

• Palella FJ Jr, Delaney KM, Moorman AC, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
   PubMed Web of Science ®Google Scholar
• Ammassari A, Trotta MP, Shalev N, Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther 2012;17(5):785-92
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Last accessed 7 March 2012]
   Google Scholar
• Maitland D, Jackson A, Osorio J, Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008;9:667-72
   PubMed Web of Science ®Google Scholar
• Molina JM, Journot V, Morand-Joubert L, Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis 2005;191:830-9
   PubMed Web of Science ®Google Scholar
• Molina JM, Podsadecki TJ, Johnson MA, A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007;23:1505-14
   PubMed Web of Science ®Google Scholar
• Portsmouth SD, Osorio J, McCormick K, Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005;6:185-90
   PubMed Web of Science ®Google Scholar
• Cooper V, Moyle GJ, Fisher M, Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care 2011;23:705-13
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009;48:484-8
   PubMed Web of Science ®Google Scholar
• Raboud J, Li M, Walmsley S, Once daily dosing improves adherence to antiretroviral therapy. AIDS Behav 2011;15:1397-409
   PubMed Web of Science ®Google Scholar
• Elion R, Cohen C, Gathe J, Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS 2011;25:1881-6
   PubMed Web of Science ®Google Scholar
• Mathias AA, German P, Murray BP, Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9
   PubMed Web of Science ®Google Scholar
• Antiviral Drugs Advisory Committee Meeting Briefing Document. NDA 203-100; 11 May 2012. Food and Drug Administration. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM303397.pdf [Last accessed 27 May 2012]
   Google Scholar
• DeJesus E, Rockstroh JK, Henry K, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379:2429-38
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults. clinicaltrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01565850 [Last accessed 24 August 2012]
   Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-106
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D, Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23:1679-88
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr, Rockstroh JK, Reynes J, Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11:907-15
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006;296:769-81
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-73
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53:807-16
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-37
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-61
   PubMed Web of Science ®Google Scholar
• Cooper DA, Heera J, Goodrich J, Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-13
   PubMed Web of Science ®Google Scholar
• Nunez M, Soriano V, Martin-Carbonero L, SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials 2002;3:186-94
   PubMedGoogle Scholar
• Squires K, Lazzarin A, Gatell JM, Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011-19
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63
   PubMed Web of Science ®Google Scholar
• Molina JM, Cahn P, Grinsztejn B, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-46
   PubMed Web of Science ®Google Scholar
• Gathe J, Andrade-Villanueva J, Santiago S, Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther 2011;16:759-69
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011;204:1191-201
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55:49-57
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Fine D, Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23:1547-56
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79
   PubMed Web of Science ®Google Scholar
• Malan DR, Krantz E, David N, Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47:161-7
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323-32
   PubMed Web of Science ®Google Scholar
• Ortiz R, Dejesus E, Khanlou H, Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008;22:1389-97
   PubMed Web of Science ®Google Scholar
• Gathe J, da Silva BA, Cohen DE, A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009;50:474-81
   PubMed Web of Science ®Google Scholar
• Montaner JS, Schutz M, Schwartz R, Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. MedGenMed 2006;8:36
   PubMedGoogle Scholar
• Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008;13:375-80
   PubMed Web of Science ®Google Scholar
• Gathe JC Jr, Ive P, Wood R, SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18:1529-37
   PubMed Web of Science ®Google Scholar
• Smith KY, Weinberg WG, Dejesus E, Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5:5
   PubMedGoogle Scholar
• Sax PE, DeJesus E, Mills A, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439-48
   PubMed Web of Science ®Google Scholar
• Sax P, DeJesus E, Mills A, The Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF ("Quad") Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naive HIV-1 Infected Subjects: Primary Results of Study GS-US-236-0102. 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle, Washington
   Google Scholar
• van Lunzen J, Maggiolo F, Arribas JR, Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012;12:111-18
   PubMed Web of Science ®Google Scholar
• Soriano V, Cox J, Eron J, Dolutegravir (DTG, S/GSK1349572) Treatment of Subjects with Raltegravir (RAL) Resistance: Viral Suppression at Week 24 in the VIKING Study. 13th European AIDS Conference; 12 – 15 October 2011; Belgrade, Serbia
   Google Scholar
• Underwood MR, Johns BA, Sato A, The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012; Epub ahead of print
   PubMedGoogle Scholar
• Johnson VA, Calvez V, Gunthard HF, 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19:156-64
   PubMedGoogle Scholar
• Miller A, Fransen S, Huang W, Temporal order of resistance emergence for lamivudine/emtricitabine, efavirenz and raltegravir in treatment-naive patients. International HIV and Hepatitis Drug Resistance Workshop; 8 – 12 June 2010; Dubrovnik. Croatia
   Google Scholar
• Dejesus E, Young B, Morales-Ramirez JO, Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009;51:163-74
   PubMed Web of Science ®Google Scholar
• Hodder SL, Mounzer K, Dejesus E, Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010;24:87-96
   PubMed Web of Science ®Google Scholar
• Rosso R, Di Biagio A, Maggiolo F, Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care 2012;24:54-8
   PubMed Web of Science ®Google Scholar
• Mills A, Cohen C, Dejesus E, Switching from Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV-1 Infected Subjects. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy 2011; 17 – 20 September 2011; Chicago, Illinois
   Google Scholar
• Spreen W, Ford S, Chen S, Pharmacokinetics, safety and tolerability of the HIV integrase inhibitor S/GSK1265744 long acting parenteral nanosuspension following single dose administration to healthy adults. XIX International AIDS Conference; 22 – 27 July 2012; Washington, District of Columbia
   Google Scholar
• van't Klooster G, Verloes R, Baert L, Long-acting TMC278, a parenteral depot formulation delivering sustained NNRTI plasma concentrations in preclinical and clinical settings. 15th Conference on Retroviruses and Opportunistic Infections; 3 – 6 February 2008; Boston, Massachusetts
   Google Scholar
• Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. World Health Organization. Available from: whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf [Last accessed 24 August 2012]
   Google Scholar
• Guidelines Clinical Management and Treatment of HIV-infected Adults in Europe. Version 5-3. European AIDS Clinical Society. Available from: http://www.isigrp.com/isia/updf.jsp?c=115787&y=2011&f=03-08gild.pdf&s=5KXDG4ztdOJEXLyCnSy2BA== [Last accessed 24 August 2012]
   Google Scholar
• Thompson MA, Aberg JA, Hoy JF, Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402
   PubMed Web of Science ®Google Scholar
• South African Treatment Guideline 2010 Department Health: republic of South Africa. Available from: http://www.uj.ac.za/EN/CorporateServices/ioha/Documentation/Documents/ART%20Guideline.pdf [Last accessed 24 August 2012]
   Google Scholar
• Sungkanuparph S, Techasathit W, Utaipiboon C, Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed 2010;4:515-28
   Web of Science ®Google Scholar
• Sustiva (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020972s040lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Viramune (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020636s039_020933s030lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Viramune XR (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201152s002lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Edurant (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• ter Heine R, Scherpbier HJ, Crommentuyn KM, A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008;13:779-87
   PubMed Web of Science ®Google Scholar
• Madruga J, Cassetti I, Etzel A, The Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-naive Patients Through Seven Years. 16th Conference on Retroviruses and Opportunistic Infections; 8 – 11 February 2009; Montreal, Canada
   Google Scholar
• Wilkin A, Pozniak AL, Morales-Ramirez J, Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 2012;28:437-46
   PubMed Web of Science ®Google Scholar
• Ziagen (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020977s024,020978s028lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Videx EC (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021183s025lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Emtriva (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021500s010,021896s004lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Epivir (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020564s031,020596s030lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Viread (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021356s041lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Piliero P, Shachoy-Clark A, Para M, A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK Protocol CNA10905). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 14 – 17 September 2003; Chicago, Illinois
   Google Scholar
• Ahluwalia G, Cooney DA, Hartman NR, Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine. Drug Metab Dispos 1993;21:369-76
   PubMed Web of Science ®Google Scholar
• Wang L, Begley J, Feng J, Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing. 14th International AIDS Conference; Barcelona, Spain; 2002
   Google Scholar
• Hawkins T, Veikley W, StClaire R, Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens. 5th International workshop on clinical pharmacology of HIV therapy; Rome, Italy; 2007
   Google Scholar
• DeJesus E, Herrera G, Teofilo E, Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004;39:1038-46
   PubMed Web of Science ®Google Scholar
• Jayaweera D, Dejesus E, Nguyen KL, Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naive HIV-1-infected patients over 96 weeks. HIV Clin Trials 2009;10:375-84
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pozniak AL, Gallant JE, Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74-8
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361:2230-40
   PubMed Web of Science ®Google Scholar
• Tan DH, Chan K, Raboud J, Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr 2011;58:38-46
   PubMed Web of Science ®Google Scholar
• Ribaudo HJ, Benson CA, Zheng Y, No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011;52:929-40
   PubMed Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26
   PubMed Web of Science ®Google Scholar
• Kaletra (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021226s035lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Prezista (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s022lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Lexiva (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021548s029,022116s013lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Invirase (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020628s038,021785s015lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Dejesus E, Mills A, Bhatti L, A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients. Int J Clin Pract 2011;65:1240-9
   PubMedGoogle Scholar
• Gatell J, Salmon-Ceron D, Lazzarin A, Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007;44:1484-92
   PubMed Web of Science ®Google Scholar
• Hicks CB, DeJesus E, Sloan LM, Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses 2009;25:395-403
   PubMed Web of Science ®Google Scholar
• Najem GR, Okuzu EI. International comparison of medical students' perceptions of HIV infection and AIDS. J Natl Med Assoc 1998;90:765-74
   PubMedGoogle Scholar
• Madruga JV, Berger D, McMurchie M, Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007;370:49-58
   PubMed Web of Science ®Google Scholar
• Reyataz (package insert). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021567s028lbl.pdf [Last accessed 27 May 2012]
   Google Scholar
• Vanhove GF, Kastrissios H, Gries JM, Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997;41:2428-32
   PubMed Web of Science ®Google Scholar
• Gathe JC Jr, Wood R, Sanne I, Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin Ther 2006;28:745-54
   PubMed Web of Science ®Google Scholar
• Pulido F, Estrada V, Baril JG, Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials 2009;10:76-87
   PubMed Web of Science ®Google Scholar
• Murphy RL, da Silva BA, Hicks CB, Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2008;9:1-10
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh J, Henry K, Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate with atazanavir/ritonavir-boosted plus emtricitabine/tenofovir disoproxil fumarate in treatment naive HIV-1+ subjects showing efficacy, safety, and pharmacokinetics. 19th CROI; Seattle, Washington; 2012
   Google Scholar
• Lopez-Cortes LF, Viciana P, Ruiz-Valderas R, Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study. AIDS Res Ther 2010;7:5
   PubMedGoogle Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Last accessed 7 May 2012]
   Google Scholar
• Molina JM, Lamarca A, Andrade-Villanueva J, Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012;12:27-35
   PubMed Web of Science ®Google Scholar
• Zolopa AR, Berger DS, Lampiris H, Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010;201:814-22
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Staszewski S, Plettenburg A, Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS 2009;23:2115-22
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 single table regimen versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate single table regimen in HIV 1 infected, antiretroviral treatment naive adults. clinicaltrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01497899?term=GS-7340+AND+phase+II&rank=18 [Last accessed 17 July 2012]
   Google Scholar
• Comparison of Elvucitabine/Efavirenz/Tenofovir versus Lamivudine/Efavirenz/Tenofovir in HIV-1 infected, treatment naive subjects. clinicaltrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00350272 [Last accessed 17 July 2012]
   Google Scholar
• DeJesus E, Saple D, Morales-Ramirez J, Elvucitabine vs Lamivudine with Tenofovir and Efavirenz in ART-naive HIV-1-infected Patients: 96-week Final Results. 17th Conference on Retroviruses and Opportunistic Infections; 16 – 19 February 2010; San Francisco, California
   Google Scholar
• Cohen C, Elion R, Ruane P, Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25:F7-12
   PubMed Web of Science ®Google Scholar
• Lee WA, He GX, Eisenberg E, Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005;49:1898-906
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Chen S, Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012;56:1627-9
   PubMed Web of Science ®Google Scholar
• Vernazza P, Wang C, Pozniak A, Efficacy and safety of lersivirine (UK-453,061) vs. efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicentre, randomised, double-blind, phase IIb trial (study A5271015). 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17 – 20 July 2011; Rome, Italy
   Google Scholar
• Georgiev V. National institute of allergy and infectious diseases, NIH: impact on global health. Publisher Humana Press; Bethesda, MD, USA: 2009
   Google Scholar
• Goethals O, Clayton R, Van Ginderen M, Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008;82:10366-74
   PubMed Web of Science ®Google Scholar
• Nguyen HL, Ruxrungtham K, Delaugerre C. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. Intervirology 2012;55:287-95
   PubMedGoogle Scholar